August 13, 2019 / 11:10 AM / 9 days ago

Deciphera Pharma's late-stage stomach cancer study meets main goal

Aug 13 (Reuters) - Deciphera Pharmaceuticals Inc said on Tuesday its late-stage study met the main goal of progression-free survival in patients with a form of stomach cancer.

The study tested the treatment, ripretinib, in 129 patients with advanced gastrointestinal stromal tumors. (Reporting by Aakash Jagadeesh Babu in Bengaluru; Editing by Shinjini Ganguli)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below